ArticleAmerican journal of translational research2023
Additional hemoperfusion for patients receiving maintenance hemodialysis: a retrospective analysis.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Serum Zn and Ca correlate with false positive non-invasive prenatal test results.American journal of translational research · 2025Article
- Treatment outcomes and determinants of combined hemodialysis-hemoperfusion therapy in chronic glomerulonephritis.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the efficacy of hemodialysis combined with hemoperfusion with acupuncture on calcium-phosphorus metabolism disorder (CPMD) of patients who had received maintenance hemodialysis and its effect on intact parathyroid hormone (iPTH) and nutritional status.
methodsData from 142 patients who were treated and given maintenance hemodialysis in Baoji People's Hospital from March 2018 to February 2020 were analyzed retrospectively. Patients treated with hemodialysis and acupuncture-moxibustion adjuvant therapy were enrolled into the control group (n=58), while those treated with hemoperfusion in addition to hemodialysis and acupuncture-moxibustion adjuvant therapy were enrolled into the research group (n=84). The two groups were compared in terms of changes in iPTH, calcium-phosphorus product, serum calcium (Ca), serum phosphorus (P), β2 microglobulin (β2-MG), serum albumin (Alb), creatinine (Scr) and urea nitrogen (BUN). The clinical efficacy in the two groups was compared after therapy, and the two groups were also compared in the improvement of immune function-related indexes (IgG and IgM) and the changes of nutrition-related indexes (Alb, prealbumin (PA) and hemoglobin (Hb)) before and after treatment. A risk prediction model was constructed based on LASSO regression to evaluate the predictive value of the risk score for efficacy of patients.
resultsAfter treatment, the research group presented significantly lower levels of P, iPTH, and calcium-phosphorus product than the control group, but a significantly higher Ca level than the control group (all P<0.05). In addition, after treatment, the research group showed significantly lower levels of β2-MG, Scr and BUN but a higher Alb level than the control group (all P<0.05). After treatment, the research group had a greater improvement in immune function-related indexes (IgG and IgM) than the control group (all P<0.05), while the control group had significantly decreased Alb, PA and Hb after treatment (all P<0.05), but the levels of these in the research group did not change greatly (all P>0.05). Risk scoring formula was constructed: risk score = (dialysis time * 0.057123881) + (Ca * -0.100413548) + (P * 0.100419363) + (calcium and phosphorus product * 0.03872268) + (iPTH * 0.000358779). According to inter-group comparison of risk score, the Improvement group got a lower risk score than the Non-improvement group (P<0.0001). Moreover, according to ROC curve-based analysis, the area under the curve of risk score in predicting the efficacy of patients was 0.991.
conclusionHemodialysis combined with acupuncture and blood perfusion can control the immune regulation by increasing the blood calcium content without affecting nutritional status, but it has no significant effect on the efficacy in patients.
Indexed as
Identifiers
37434811PMC10331684W4383998395What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.